Semaglutide: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
==Synthesis== | ==Synthesis== | ||
Semaglutide is made by Novo Nordisk, and the details are proprietary. The product is semisynthetic, with the bulk of the peptide made in recombinant yeast<ref name="euro">Committee for Medicinal Products for Human use (CHMP). European Medicines Agency (EMA). (2018). | Semaglutide is made by Novo Nordisk, and the details are proprietary<ref>PMID: 37505513</ref>. The product is semisynthetic, with the bulk of the peptide made in recombinant yeast<ref name="euro">Committee for Medicinal Products for Human use (CHMP). European Medicines Agency (EMA). (2018). | ||
https://www.ema.europa.eu/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf</ref> and the fatty acid and the first two amino acids attached afterwards. Because the second lysine of GLP-1 is replaced by an arginine in semaglutide, the fatty acid is attached to a single lysine, simplifying the coupling between peptide and linker-attached fatty acid. | https://www.ema.europa.eu/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf</ref> and the fatty acid and the first two amino acids attached afterwards. Because the second lysine of GLP-1 is replaced by an arginine in semaglutide, the fatty acid is attached to a single lysine, simplifying the coupling between peptide and linker-attached fatty acid. | ||
